Top

Published in:

Open Access 01-12-2016 | Study protocol

Study protocol: a randomised controlled trial of cognitive remediation for a national cohort of forensic mental health patients with schizophrenia or schizoaffective disorder

Authors: Ken O’Reilly, Gary Donohoe, Danny O’Sullivan, Ciaran Coyle, Ronan Mullaney, Paul O’Connell, Catherine Maddock, Andrea Nulty, Padraic O’Flynn, Carina O’Connell, Harry G Kennedy

Published in: BMC Psychiatry | Issue 1/2016

Abstract

Background

Evidence is accumulating that cognitive remediation therapy (CRT) is an effective intervention for patients with schizophrenia or schizoaffective disorder. To date there has been no randomised controlled trial (RCT) cohort study of cognitive remediation within a forensic hospital. The goal of this study is to examine the effectiveness of a trial of cognitive remediation for forensic mental health patients with schizophrenia or schizoaffective disorder.

Methods

An estimated sixty patients will be enrolled in the study. Participants will be randomised to one of two conditions: CRT with treatment as usual (TAU), or TAU. CRT will consist of 42 individual sessions and 14 group sessions. The primary outcome measure for this study is change in cognitive functioning using the MATRICS Consensus Cognitive Battery (MCCB). Secondary outcomes include change in social and occupational functioning, disorganised symptoms, negative symptoms, violence, participation in psychosocial treatment and recovery. In addition to these effectiveness measures, we will examine patient satisfaction.

Discussion

Cognitive difficulties experienced by schizophrenia spectrum patients are associated with general functioning, ability to benefit from psychosocial interventions and quality of life. Research into the treatment of cognitive difficulties within a forensic setting is therefore an important priority. The results of the proposed study will help answer the question whether cognitive remediation improves functional outcomes in forensic mental health patients with schizophrenia or schizoaffective disorder. Forensic mental health patients are detained for the dual purpose of receiving treatment and for public protection. There can be conflict between these two roles perhaps causing forensic services to have an increased length of stay compared to general psychiatric admissions. Ultimately a focus on emphasising cognition and general functioning over symptoms may decrease tension between the core responsibilities of forensic mental health services.

Trial Registration

ClinicalTrials.gov Identifier: NCT02360813. Trial registered Feb 4th 2015 and last updated May 1^st 2015.

Kennedy H. Therapeutic uses of security: mapping forensic mental health services by stratified risk. Advances in Psychiatric Treatment. 2002;8:433–43.CrossRef

McFadyen JA. Safe, sound and supportive: forensic mental health services. Br J Nurs. 1999;8:1436–40.PubMedCrossRef

McInerney C, Davoren M, Flynn G, Mullins D, Fitzpatrick M, Caddow M, et al. Implementing a court diversion and liaison scheme in a remand prison by systematic screening of new receptions: a 6 year participatory action research study of 20,084 consecutive male remands. International Journal of Mental Health Systems. 2013;7:18. doi:10.1186/1752-4458-7-18.PubMedPubMedCentralCrossRef

Packer IK. Evaluation of criminal responsibility. New York: Oxford University Press; 2009.CrossRef

Ireland. Criminal Law (insanity) Act 2010. Irish Statute Book. 2010 http://www.irishstatutebook.ie/2010/en/act/pub/0040/index.html.

Buchanan A, Grounds A. Forensic psychiatry and public protection. Br J Psychiatry. 2011;198:420–3. doi:10.1192/bjp.bp.111.095471.PubMedCrossRef

Andreasson H, Nyman M, Krona H, Meyer L, Anckarsäter H, Nilsson T, et al. Predictors of length of stay in forensic psychiatry: the influence of perceived risk of violence. Int J Law Psychiatry. 2014;37:635–42. doi:10.1016/j.ijlp.2014.02.038. Epub 2014 Mar 14.PubMedCrossRef

Sharma A, Dunn W, O'Toole C, Kennedy HG. The virtual institution: cross-sectional length of stay in general adult and forensic psychiatry beds. Int J Ment Health Syst. 2015;9:25. doi:10.1186/s13033-015-0017-7.eCollection2015.PubMedPubMedCentralCrossRef

Fazel S, Fimińska Z, Cocks C, Coid J. Patient outcomes following discharge from secure psychiatric hospitals: systematic review and meta-analysis. Br J Psychiatry. 2016;208:17-25. doi: 10.1192/bjp.bp.114.149997.PubMedCrossRef

10.

Davoren M, Byrne O, O'Connell P, O'Neill H, O'Reilly K, Kennedy HG. Factors affecting length of stay in forensic hospital setting: need for therapeutic security and course of admission. BMC Psychiatry. 2015;15(1):301. doi:10.1186/s12888-015-0686-4.PubMedPubMedCentralCrossRef

11.

Ricketts D, Carnell H, Davies S, Kaul A, Duggan C. First admissions to a regional secure unit over a 16-year period: Changes in demographic and service characteristics. Journal of Forensic Psychiatry. 2001;12:78–89.CrossRef

12.

Shah A, Waldron G, Boast N, Coid JW, Ullrich S. Factors associated with length of admission at a medium secure forensic psychiatric unit. Journal of Forensic Psychiatry and Psychology. 2011;22:496–512.CrossRef

13.

Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2012;5, CD008016. doi:10.1002/14651858.CD008016.pub2.PubMed

14.

Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. CATIE Investigators; Neurocognitive Working Group. Arch Gen Psychiatry. 2007;64:633–47.PubMedCrossRef

15.

Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry. 2010;71:1115–24. doi:10.4088/JCP.10r06264yel.PubMedPubMedCentralCrossRef

16.

Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry. 2007;164:428–36. PMID:17329467.PubMedCrossRef

17.

Kirkpatrick B, Fischer B. Subdomains within the negative symptoms of schizophrenia: commentary. Schizophr Bull. 2006;32:246–9.PubMedPubMedCentralCrossRef

18.

Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry. 1996;153:321–30.PubMedCrossRef

19.

Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull. 2000;26:119–36.PubMedCrossRef

20.

Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72:41–51.PubMedCrossRef

21.

Velligan DI, Mahurin RK, Diamond PL, Hazleton BC, Eckert SL, Miller AL. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr Res. 1997;25:21–31.PubMedCrossRef

22.

Norman RM, Malla AK, McLean T, Voruganti LP, Cortese L, McIntosh E, et al. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatr Scand. 2000;102:303–9.PubMedCrossRef

23.

Lysaker PH, Davis LW. Social function in schizophrenia and schizoaffective disorder: associations with personality, symptoms and neurocognition. Health Qual Life Outcomes. 2004;2:15.PubMedPubMedCentralCrossRef

24.

Kurtz MM, Moberg PJ, Ragland JD, Gur RC, Gur RE. Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study. Schizophr Bull. 2005;31:167–74.PubMedCrossRef

25.

Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162:495–506.PubMedCrossRef

26.

Cohen AS, Saperstein AM, Gold JM, Kirkpatrick B, Carpenter WT Jr, Buchanan RW. Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull. 2007;33:1201–12.PubMedPubMedCentralCrossRef

27.

Kahn RS, Keefe RS. Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry. 2013;70:1107–12.PubMedCrossRef

28.

Brekke JS, Hoe M, Long J, Green MF. How neurocognition and social cognition influence functional change during community-based psychosocial rehabilitation for individuals with schizophrenia. Schizophr Bull. 2007;33:1247–56.PubMedPubMedCentralCrossRef

29.

Ventura J, Hellemann GS, Thames AD, Koellner V, Nuechterlein KH. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr Res. 2009;113(2-3):189–99. doi:10.1016/j.schres.2009.03.035.PubMedPubMedCentralCrossRef

30.

O'Connell M, Farnworth L. Occupational Therapy in Forensic Psychiatry: A Review of the Literature and a Call for a United and International Response. Journal of International Medical Research. 2012;40:2251–66.PubMedCrossRef

31.

Williams E, Ferrito M, Tapp T. Cognitive-behavioural therapy for schizophrenia in a forensic mental health setting. Journal of Forensic Practice. 2014;16:68–77.CrossRef

32.

Blackburn R. What works with mentally disordered offenders. Psychology Crime & Law. 2004;10:297–308.CrossRef

33.

Lindqvist P, Skipworth J. Finding the evidence in forensic rehabilitation. Br J Psychiatry. 2000;177:372.PubMedCrossRef

34.

Lindqvist P, Skipworth J. Evidence based rehabilitation in forensic psychiatry. Br J Psychiatry. 2000;176:320–3.PubMedCrossRef

35.

Skeem JL, Steadman HJ, Manchak SM. Applicability of the Risk-Need-Responsivity Model to Persons With Mental Illness Involved in the Criminal Justice System. Psychiatr Serv. 2015;66(9):916–22.PubMedCrossRef

36.

Cullen AE, Clarke AY, Kuipers E, Hodgins S, Dean K, Fahy T. A multisite randomized trial of a cognitive skills program for male mentally disordered offenders: violence and antisocial behavior outcomes. J Consult Clin Psychol. 2012;80:1114–20. doi:10.1037/a0030291.PubMedCrossRef

37.

Rees-Jones A, Gudjonsson G, Young S. A multi-site controlled trial of a cognitive skills program for mentally disordered offenders. BMC Psychiatry. 2012;12:44.PubMedPubMedCentralCrossRef

38.

O’Reilly K, Donohoe G, Coyle C, O’Sullivan D, Rowe A, Losty M, et al. Prospective cohort study of the relationship between neuro-cognition, social cognition and violence in forensic patients with schizophrenia and schizoaffective disorder. BMC Psychiatry. 2015;15:155. doi:10.1186/s12888-015-0548-0.PubMedPubMedCentralCrossRef

39.

Lezak MD, Howieson DB, Bigler ED, Tranel D. Neuropsychological Assessment (5th ed). New York: Oxford University Press; 2012.

40.

Ochsner KN. The social-emotional processing stream: five core constructs and their translational potential for schizophrenia and beyond. Biol Psychiatry. 2008;64:48–61. doi:10.1016/j.biopsych.2008.04.024.PubMedPubMedCentralCrossRef

41.

Carr A. What Works with Children, Adolescents and Adults? A Review of Research on the Effectiveness of Psychotherapy. London: Routledge; 2009.

42.

Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011;168:472–85. doi:10.1176/appi.ajp.2010.10060855.PubMedCrossRef

43.

Wykes T, Spaulding WD. Thinking about the future cognitive remediation therapy--what works and could we do better? Schizophr Bull. 2011;37 Suppl 2:S80–90. doi:10.1093/schbul/sbr064.PubMedPubMedCentralCrossRef

44.

Cella M, Reeder C, Wykes T. Lessons learnt? The importance of metacognition and its implications for Cognitive Remediation in schizophrenia. Front Psychol. 2015;6:1259. doi:10.3389/fpsyg.2015.01259.PubMedPubMedCentralCrossRef

45.

Rose D, Wykes T, Farrier D, Doran AM, Sporle T, Bogner D. What Do Clients Think of Cognitive Remediation Therapy?: A Consumer-Led Investigation of Satisfaction and Side Effects. American Journal of Psychiatric Rehabilitation. 2008;11:181–204. doi:10.1080/15487760801963694.CrossRef

46.

Spaulding WD, Reed D, Sullivan M, Richardson C, Weiler M. Effects of cognitive treatment in psychiatric rehabilitation. Schizophr Bull. 1999;25:657–76.PubMedCrossRef

47.

Taylor R, Cella M, Csipke E, Heriot-Maitland C, Gibbs C, Wykes T. Tackling Social Cognition in Schizophrenia: A Randomized Feasibility Trial. Behav Cogn Psychother. 2015;9:1–12.CrossRef

48.

Ahmed AO, Hunter KM, Goodrum NM, Batten NJ, Birgenheir D, Hardison E, et al. A randomized study of cognitive remediation for forensic and mental health patients with schizophrenia. J Psychiatr Res. 2015;68:8–18. doi:10.1016/j.jpsychires.2015.05.013.PubMedCrossRef

49.

Ullrich S, Keers R, Coid JW. Delusions, anger, and serious violence: new findings from the MacArthur Violence Risk Assessment Study. Schizophr Bull. 2014;40:1174–81. doi:10.1093/schbul/sbt126.PubMedPubMedCentralCrossRef

50.

Witt K, Van Dorn R, Fazel S. Risk factors for violence in psychosis: systematic review and meta-regression analysis of 110 studies. PLoS One. 2013;8(2):e55942. doi:10.1371/journal.pone.0055942. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/f4abfc20-5a38-4dec-aa46-7d28018bbe38.PubMedPubMedCentralCrossRef

51.

Webster CD, Douglas KS, Eaves D, Hart SD. HCR–20: assessing risk for violence. Burnaby: Mental Health Law and Policy Institute, Simon Fraser University; 1997.

52.

Schizophrenia Commission. The Abandoned Illness: A Report by the Schizophrenia Commission. 2012. Rethink Mental Illness.

53.

Fazel S, Wolf A, Pillas D, Lichtenstein P, Långström N. Suicide, Fatal Injuries, and Other Causes of Premature Mortality in Patients With Traumatic Brain Injury A 41-Year Swedish Population Study. JAMA Psychiatry. 2014;71:326–33. doi:10.1001/jamapsychiatry.2013.3935.PubMedPubMedCentralCrossRef

54.

Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull. 2008;34:523–37.PubMedPubMedCentralCrossRef

55.

First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P): Biometrics Research, New York State Psychiatric Institute, November 2002.

56.

Corp IBM. IBM SPSS Statistics for Windows, Version 22.0. IBM Corp. Released: Armonk, NY; 2013.

57.

Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry. 2003;64:663–7.PubMedCrossRef

58.

Haddad P, Lambert T, Lauriello J. Antipsychotic Long-acting Injections. London: Oxford University Press; 2010. p. 26.CrossRef

59.

Taylor D, Paton C, Kapur S, editors. The Maudsley prescribing guidelines in psychiatry. London: John Wiley & Sons; 2012.

60.

Wechsler D. Test of Pre-morbid Functioning - UK Version (TOPF UK). Pearson Corporation 2011.

61.

Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165:203–13. doi:10.1176/appi.ajp.2007.07010042.PubMedCrossRef

62.

Baron-Cohen S, Wheelwright S, Hill J, Raste Y, Plumb I. The "Reading the Mind in the Eyes" Test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry. 2001;42(2):241–51.PubMedCrossRef

63.

Stone VE, Baron-Cohen S, Knight RT. Frontal lobe contributions to theory of mind. J Cogn Neurosci. 1998;10:640–56.PubMedCrossRef

64.

Rybarczyk B. Social and Occupational Functioning Assessment Scale (SOFAS). In: Kreutzer J, DeLuca J, Caplan B, editors. LXIII, Encyclopedia of Clinical Neuropsychology vol 1. New York: Springer Reference; 2011. p. 2313. (Print) 978-0-387-79948-3. ISBN 978-0-387-79947-6.CrossRef

65.

Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale. (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–76.PubMedCrossRef

66.

Kring AM, Gur RE, Blanchard JJ, Horan WP, Reise SP. The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. Am J Psychiatry. 2013;170:165–72. doi:10.1176/appi.ajp.2012.12010109.PubMedPubMedCentralCrossRef

67.

Medalia A, Revheim N, Herlands. Cognitive remediation for psychological disorders. New York: Oxford University Press; 2009.CrossRef

68.

Gastonguay LG, Beutler LE. Principles of therapeutic change. New York: Oxford University Press; 2006.

69.

Henggeler SW, Schoenwald KS, Borduin CM, Cunningham PB. Multisystemic treatment of antisocial behaviour in children and adolescents. New York. London: The Guilford press; 1998.

70.

Davoren M, O'Dwyer S, Abidin Z, Naughton L, Gibbons O, Doyle E, et al. Prospective in-patient cohort study of moves between levels of therapeutic security: the DUNDRUM-1 triage security, DUNDRUM-3 programme completion and DUNDRUM-4 recovery scales and the HCR-20. BMC Psychiatry. 2012;12:80. doi:10.1186/1471-244X-12-80.PubMedPubMedCentralCrossRef

71.

Wampold B. How important are the common factors in psychotherapy? An update World Psychiatry. 2015;14:270–7.PubMedCrossRef

72.

Huddy V, Reeder C, Kontis D, Wykes T, Stahl D. The effect of working alliance on adherence and outcome in cognitive remediation therapy. J Nerv Ment Dis. 2012;200:614–9. doi:10.1097/NMD.0b013e31.PubMedCrossRef

73.

Subramaniam K, Kounios J, Parrish TB, Jung-Beeman M. A brain mechanism for facilitation of insight by positive affect. J Cogn Neurosci. 2009;21:415–32. doi:10.1162/jocn.2009.21057.PubMedCrossRef

74.

Savine AC, Braver TS. Local and global effects of motivation on cognitive control. Cogn Affect Behav Neurosci. 2012;12:692–718. doi:10.3758/s13415-012-0113-y.PubMedCrossRef

75.

Medalia A, Saperstein A. The role of motivation for treatment success. Schizophr Bull. 2011;37 Suppl 2:S122–8. doi:10.1093/schbul/sbr063.PubMedPubMedCentralCrossRef

76.

Kennedy HG. Therapeutic Uses of Security: mapping forensic mental health services by stratifying risk. In: Bloom H, Webster CD, editors. Essential Writings in Violence Risk Assessment and Management. Centre for Addiction and Mental Health, Toronto: 2007. p 537–553.

77.

Pillay SM, Oliver B, Butler L, Kennedy HG. Risk stratification and the care pathway. Irish Journal of Psychological Medicine. 2008;25:123–7.

78.

Kennedy HG, O’Neill C, Flynn G, Gill P. The DUNDRUM toolkit. Dangerousness understanding, recovery and urgency manual (the DUNDRUM Quartet) V1.0.21 (18/03/10), Four structured professional judgment instruments for admission triage, urgency, treatment completion and recovery assessments. Dublin: Trinity College Dublin; 2010. http:// hdl.handle.net/ 2262/39131.

79.

Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollock BG. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry. 2009;166:1055–62. doi:10.1176/appi.ajp.2009.09010017.PubMedPubMedCentralCrossRef

80.

Mayer JD, Salovey P, Caruso DR. Mayer-Salovey-Caruso. Emotional Intelligence Test (MSCEIT): User’s Manual. Toronto, Ontario: Multi-Health Systems, Inc.; 2002.

81.

Mayer JD, Salovey P, Caruso DR, Sitarenios G. Measuring emotional intelligence with the MSCEIT V2.0. Emotion. 2003;3:97–105.PubMedCrossRef

82.

Cella M, Reeder C, Wykes T. It is all in the factors: effects of cognitive remediation on symptom dimensions. Schizophr Res. 2014;156:60–2. doi:10.1016/j.schres.2014.03.032.PubMedCrossRef

83.

Montori VM, Guyatt GH. Intention-to-treat principle. CMAJ. 2001;165:1339–41.PubMedPubMedCentral

84.

Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: Wiley; 1987.CrossRef

85.

Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Biometrics. 2010;66:1202–8. doi:10.1111/j.1541-0420.2010.01405.x.CrossRef

86.

Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry. 2013;70:913–20. doi:10.1001/jamapsychiatry.2013.19.PubMedCrossRef

87.

Lambert MJ, Barley DE. Research summary on the therapeutic relationship and psychotherapy outcome. In: Norcross JC, editor. Psychotherapy relationships that work: Therapist contributions and responsiveness to patients (pp. 17–). Oxford, England: Oxford University Press; 2002.

Title: Study protocol: a randomised controlled trial of cognitive remediation for a national cohort of forensic mental health patients with schizophrenia or schizoaffective disorder
Authors: Ken O’Reilly
Gary Donohoe
Danny O’Sullivan
Ciaran Coyle
Ronan Mullaney
Paul O’Connell
Catherine Maddock
Andrea Nulty
Padraic O’Flynn
Carina O’Connell
Harry G Kennedy
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: BMC Psychiatry / Issue 1/2016
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/s12888-016-0707-y

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Study protocol: a randomised controlled trial of cognitive remediation for a national cohort of forensic mental health patients with schizophrenia or schizoaffective disorder

Abstract

Background

Methods

Discussion

Trial Registration

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Discussion

Trial Registration

Please log in to get access to this content

Other articles of this Issue 1/2016

Chronobiology, sleep-related risk factors and light therapy in perinatal depression: the “Life-ON” project

Enhancing reciprocal partner support to prevent perinatal depression and anxiety: a Delphi consensus study

Gut to brain interaction in Autism Spectrum Disorders: a randomized controlled trial on the role of probiotics on clinical, biochemical and neurophysiological parameters

An integrated workplace mental health intervention in a policing context: Protocol for a cluster randomised control trial

Adult attention-deficit/hyperactivity disorder and nicotine withdrawal: a qualitative study of patient perceptions

A randomized controlled study of exposure therapy as aftercare for alcohol use disorder: study protocol